Porphyria Cutanea Tarda – a Case Report

1. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet 2010;375:924-37.10.1016/S0140-6736(09)61925-5Search in Google Scholar

2. Frank J, Poblete-Gutiérrez P. Porphyria cutanea tarda-when skin meets liver. Best Pract Res Clin Gastroenterol 2010;24:735-45.10.1016/j.bpg.2010.07.00220955974Search in Google Scholar

3. Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood 2012;120:4496-504.10.1182/blood-2012-05-423186351222922791288Search in Google Scholar

4. Cappellini MD, Brancaleoni V, Graziadei G, Tavazzi D, Di Pierro E. Porphyrias at a glance: diagnosis and treatment. Intern Emerg Med 2010;5(Suppl 1):S73-S80.10.1007/s11739-010-0449-720865478Search in Google Scholar

5. Badenas C, To-Figueras J, Phillips JD, Warby CA, Munoz C, Herrero C. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet 2009;75:346-53.10.1111/j.1399-0004.2009.01153.x380434019419417Search in Google Scholar

6. Bickers DR, Frank J. The porphyrias. In:Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller A, Leffell DJ, editors. Fitzpatrick’s dermatology in general medicine. New York: McGraw Hill; 2007. p. 1228-56.Search in Google Scholar

7. Waldenstrom J. Srudien uber porphyrie. Acta Med Scand 1937;82(Suppl):1-254.Search in Google Scholar

8. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CS, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 2000. p. 2991-3062.Search in Google Scholar

9. Bickers DR, Frank J. The porphyrias. In: Fitzpatrick TB, Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, et al. eds. Dermatology in general medicine. 6th ed. New York: McGraw Hill; 2003. p. 1435-66.Search in Google Scholar

10. de Verneuil H, Aitken G, Nordmann Y. Familial and sporadic porphyria cutanea: two different diseases. Hum Genet 1978;44:145-51.10.1007/BF00295407730158Search in Google Scholar

11. Elder GH, Lee GB, Tovey JA. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N Engl J Med 1978;299:274-8.10.1056/NEJM197808102990603661926Search in Google Scholar

12. Felsher BF, Carpio NM, Engleking DW, Nunn AT. Decreased hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda. New Engl J Med 1982;306:766-9.10.1056/NEJM1982040130613027062951Search in Google Scholar

13. Kushner J P, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest 1976;58:1089-97.10.1172/JCI108560333275993332Search in Google Scholar

14. Byrne JP, Boss JM, Dawber RP. Contaceptive pill-induced porphyria cutanea tarda presenting with onycholysis of the finger nail. Postgrad Med J 1976;52:535-8.10.1136/pgmj.52.610.5352496458981098Search in Google Scholar

15. Taylor JS. Porphyria cutanea tarda symptomatica. Cutis 1970;6:1261-74.Search in Google Scholar

16. Boffa MJ, Reed P, Weinkove C, Ead RD. Hypertrichosis as the presenting feature of porphyria cutanea tarda. Clin Exp Dermatol 1995; 20:62-4.10.1111/j.1365-2230.1995.tb01288.xSearch in Google Scholar

17. Kapoor R, Johnson RA. Porphyria cutanea tarda and hypertrichosis. N Engl J Med 2013;360(14):1356.10.1056/NEJMicm1010902Search in Google Scholar

18. Cripps DJ, Peters HA, Gocmen A, Dogramici I. Porphyria turcica due to hexachlorobenzene: a 20 to 30 year follow-up study on 204 patients. Br J Dermatol 1984;111:413-22.10.1111/j.1365-2133.1984.tb06603.xSearch in Google Scholar

19. Haberman HF, Rosenberg F, Menon IA. Porphyria cutanea tarda: comparison of cases precipitated by alcohol and estrogens. Can Med Assoc J 1975;113:653-5.Search in Google Scholar

20. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon- alpha therapy in a case of chronic hepatitis C. Dig Dis Sci 1998;43:529-33.10.1023/A:1018854906444Search in Google Scholar

21. Ashton RE, Hawk JL, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol 1984;111:609-13.10.1111/j.1365-2133.1984.tb06632.xSearch in Google Scholar

22. Valls V, Ena J, Enriquez-De-Salamanca R. Low-dose oral chloroquine in patints with porphyria cutanea tarda and lowmoderate iron overload. J Dermatol Sci 1994;7:169-75.10.1016/0923-1811(94)90092-2Search in Google Scholar

23. Kordac V, Kotal JP, Kalab M. Agents affecting porphyrin formation and secretion: implications for porphyria cutanea treatment. Semin Haematol 1989;26:16-23.Search in Google Scholar

24. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, Deleo VA, Harber LC. Porphyria cutanea tarda: clinical features and laboratory findings in 40 patients. Am J Med 1979; 67:277-86.10.1016/0002-9343(79)90403-0Search in Google Scholar

25. Sarkany RP. The management of porphyria cutanea tarda. Clin Exp Dermatol 2001; 26:225-32.10.1046/j.1365-2230.2001.00825.x11422163Search in Google Scholar

26. Ghosh SK, Bandyopadhyay D, Chatterjee G, Ghosh AP. Porphyria cutanea tarda. J Assoc Physicians India 2008;56:441.Search in Google Scholar

27. Christoph S, Huttmann A, Duhrsen U, Roth A. Porphyria cutanea tarda. Br J Haematol 2010;148:493.10.1111/j.1365-2141.2009.07821.x19622066Search in Google Scholar

28. Stolzel U, Kostler E, Schuppan D, Richter M, Wollina U, Doss MO, et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003;139:309-13. 10.1001/archderm.139.3.30912622622Search in Google Scholar